"Acadia will not want to pursue New Indications with Trofinetide and instead want to participate in the New Indications by using NNZ-2591" The agreement says that new indications are only those where Acadia is seeking to develop Trofinetide for a condition. It has nothing to do with Neuren developing NNZ 2591 for anything other than Rett and Fragile X. The notion that each time Neuren tries to do something with NNZ2591, Acadia will pop up and insist that it is developing the same thing with Trofinetide is absurd. You guys really need to get out of your Hot Copper bubble and get a smell of the real world.
NEU Price at posting:
$19.02 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)